Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
Vijoyce® - PI3K-alpha inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
NCT04589650 EPIK-P2 (CBYL719F12201)
PIK3CA-related overgrowth spectrum
Phase 2
174
Proportion of participants with a response at Week 24
Arm 1: alpelisib vs. Arm 2: placebo during the 16 first weeks, for each cohort (adult,
pediatric), with placebo patients switching to alpelisib thereafter.
Pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS)
Primary Analysis: 2023
NA
References
Abbreviations
Hematology
Biosimilars
Global Health
89 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation